Angiogenesis is important for the growth and metastasis of cancer. Inhibition of angiogenesis can therefore complement adjuvant chemotherapy of ovarian and breast cancer. Two major groups of endogenous angiogenesis inhibitors are currently investigated;proteolytic cleavage products of collagens and coagulation related proteins. Endostatin is a 20 kDa-C-terminal fragment of the non-collagenous domain (NC1) of collagen type XVIII. Endostatin treatment had resulted in varying degree of tumor growth inhibition in a number of preclinical tumor models. One of the reasons for the inconsistencies in response is due to protein folding which is affected by the type of expression system used to prepare the antiangiogenic molecule. We have identified and characterized a mutant endostatin containing a substitution of proline to alanine residue at position 125. P125A-endostatin showed increased binding to endothelial cells and inhibited angiogenesis better than the native molecule. Independent studies at NCI and in our laboratory confirmed that the mutant endostatin is better in inhibiting tumor growth than the native protein in three different tumor model systems. Therefore, it is important to understand the functional importance of substitutions at this position. Polymorphism in the NC1 domain of collagen XVIII mostly involves truncations and leads to vascular problems associated with Knobloch syndrome. The only other known mutation is D104N which however does not affect the biological activity of endostatin. No polymorphism has been yet identified at P125.
In specific aim 1 we propose to systematically generate other P125 substitutions and investigate the relative antiangiogenic potency of the mutants. Mechanistic studies will be carried out to identify mutation specific changes in the biological activity of endostatin.
In specific aim 2 we propose to evaluate the therapeutic and pharmacotoxicologic properties of mutant endostatins expressed in mammalian cells. Initial studies will focus on comparing the efficacy of protein therapy using Alzet pumps and AAV- mediated gene therapy. Based on these results we will critically evaluate a selected mutant endostatin in clinically relevant ovarian and breast cancer models. Recent studies have shown improved inhibition of tumor growth when chemotherapy was combined with mutant endostatin treatment. The mechanism of synergy between these two methods will be investigated so as to facilitate expedited clinical development of this approach, facilitate expedited clinical development of this approach.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA114340-05
Application #
8004096
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Yovandich, Jason L
Project Start
2007-02-23
Project End
2012-12-31
Budget Start
2011-01-01
Budget End
2012-12-31
Support Year
5
Fiscal Year
2011
Total Cost
$245,614
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pharmacology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Koodie, Lisa; Yuan, Hongyan; Pumper, Jeffery A et al. (2014) Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol 184:1073-84
Joshi, Hemant P; Subramanian, Indira V; Schnettler, Erica K et al. (2014) Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A 111:5331-6
Jing, Yawu; Lu, Huarui; Wu, Kailang et al. (2011) Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins. Int J Cancer 129:751-61
Subramanian, I V; Devineni, S; Ghebre, R et al. (2011) AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Gene Ther 18:145-54
Shin, Seung-Uon; Cho, Hyun-Mi; Merchan, Jaime et al. (2011) Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy. Mol Cancer Ther 10:603-14
Ramakrishnan, Sundaram (2011) Hydrogel-siRNA for cancer therapy. Cancer Biol Ther 11:849-51
Ghosh, Goutam; Subramanian, Indira V; Adhikari, Neeta et al. (2010) Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-ýý isoforms and promotes angiogenesis. J Clin Invest 120:4141-54
Bui Nguyen, T M; Nguyen, T M B; Subramanian, I V et al. (2010) Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. Gene Ther 17:606-15
Koodie, Lisa; Ramakrishnan, Sundaram; Roy, Sabita (2010) Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J Pathol 177:984-97
Geller, Melissa A; Bui-Nguyen, Tri M; Rogers, Lisa M et al. (2010) Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. Int J Gynecol Cancer 20:918-25

Showing the most recent 10 out of 15 publications